OncoBioTek Overview

  • Founded
  • 2009
  • Status
  • Out of Business
  • Employees
  • 1
  • Latest Deal Type
  • Out of Business

OncoBioTek General Information


Developer of veterinary drugs designed to offer support to treat and cure canine cancer. The company's drug is made by using a comparative oncology approach to identify and validate human cancer drugs that have significant potential for the treatment of cancer in the dog, enabling physicians to ensure efficient treatment and faster recovery of dogs suffering from cancer.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Drug Discovery
Primary Office
  • 138 Allee Des Lucioles
  • Chateauneuf Villevieille
  • 06390 Nice
  • France
+33 06 00 00 00 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

OncoBioTek Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Out of Business 01-Sep-2018 Completed Out of Business
2. Equity Crowdfunding Cancelled Generating Revenue/Not Profitable
1. Early Stage VC Completed Generating Revenue/Not Profitable
To view OncoBioTek’s complete valuation and funding history, request access »

OncoBioTek Executive Team (3)

Name Title Board Seat Contact Info
Tony Dutton Chief Executive Officer & Board Member
Robert Barthel Ph.D Founder, Board Member and Chief Scientific Officer
You’re viewing 2 of 3 executive team members. Get the full list »

OncoBioTek Board Members (5)

Name Representing Role Since
Berndt Modig Self Board Member 000 0000
Michele Garufi Self Board Member 000 0000
Robert Barthel Ph.D OncoBioTek Founder, Board Member and Chief Scientific Officer 000 0000
Tony Dutton OncoBioTek Chief Executive Officer & Board Member 000 0000
Zsolt Lavotha Self Chairman 000 0000
To view OncoBioTek’s complete board members history, request access »

OncoBioTek Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial